Global Attention
Deficit Hyperactivity Disorder (ADHD) Therapeutics Market, by Drug Type
(Stimulants (Amphetamine, Methylphenidate, Dextroamphetamine,
Dexmethylphenidate, and Lisdexamfetamine Dimesylate) and Non-stimulants
(Atomoxetine, Bupropion, Guanfacine, and Clonidine), by Age Group (Pediatric
and Adolescent, and Adult), by Distribution Channel (Specialty Clinics,
Hospital Pharmacies, Retail Pharmacies, and E-commerce), and by Region (North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is
estimated to be valued at US$ 18,169.0
million in 2020 and is expected to exhibit a CAGR of 7.1 % during the
forecast period (2020-2027), as highlighted in a new report published by
Coherent Market Insights.
Key companies are focusing on
rising approval of new products from the regulatory authority, in order to
provide better options for treatment of ADHD in pediatric and adolescent
patients, which is expected to bolster market growth over the forecast period.
For instance, in August 2018, Ironshore Pharmaceuticals & Development,
Inc., a subsidiary of Highland Therapeutics Inc., received the U.S. Food and
Drug Administration (FDA) approval for its New Drug Application (NDA) for
JORNAY PM (methylphenidate) for the treatment of attention deficit
hyperactivity disorder (ADHD) in patients aged 6 years and older.
Global Attention Deficit
Hyperactivity Disorder (ADHD) Therapeutics Market – Impact of Coronavirus
(COVID-19)
The COVID-19 pandemic has
drastically impacted each and every market across the world. Therefore,
government of various countries are taking initiatives to combat
attention-deficit hyperactivity disorder (ADHD) amid Covid-19.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/830
In order to manage attention deficit
hyperactivity disorder (ADHD) during the COVID-19 pandemic, organizations such
as National Resource Center on ADHD (NRC), Children and Adults with
Attention-Deficit/ Hyperactivity Disorder (CHADD), and others provide education
and support, and spread awareness about attention deficit hyperactivity
disorder among the patients suffering from ADHD. Such organizations are funded
by government organizations including the Centers for Disease Control and
Prevention (CDC). For instance, on July 1, 2020, the Center for Disease Control
and Prevention (CDC) highlighted the negative effects of social distancing.
They reported that social distancing increased mental stress among the people
and it is more evident in ADHD patients, due to which the behavioral problems
in some of the ADHD patients have become worse.
Browse 35 Market Data Tables and
38 Figures spread through 181 Pages and in-depth TOC on “Global Attention
Deficit Hyperactivity Disorder (ADHD) Therapeutics Market, by Drug Type
(Stimulants (Amphetamine, Methylphenidate, Dextroamphetamine,
Dexmethylphenidate, and Lisdexamfetamine Dimesylate) and Non-stimulants
(Atomoxetine, Bupropion, Guanfacine, and Clonidine), by Age Group (Pediatric
and Adolescent, and Adult), by Distribution Channel (Specialty Clinics,
Hospital Pharmacies, Retail Pharmacies, and E-commerce), and by Region (North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa)”
The market is expected to witness
significant growth during the forecast period, owing to key players focusing on
launch of new ADHD services and formation of new hubs for the diagnosis,
assessment, and treatment of ADHD. For instance, in September 2020,
Nottinghamshire Healthcare announced the launch of attention deficit
hyperactivity disorder (ADHD) service, wherein adults with ADHD in
Nottinghamshire can receive the support for diagnostic assessment and the right
treatment.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/attention-deficit-hyperactivity-disorder-treatment-market-830
Key Takeaways of the Global
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market:
The global attention deficit
hyperactivity disorder (ADHD) therapeutics market is expected to exhibit a CAGR
of 7.1% during the forecast period, owing to key companies focusing on product
launches and approval for the treatment of attention deficit hyperactivity
disorder (ADHD)
Among drug type, stimulants
segment is expected to hold major market share in the global attention deficit
hyperactivity disorder (ADHD) therapeutics market during the forecast period,
owing to an increasing number of launch of new products for the treatment of
patients with ADHD by key companies
Among age group, adults segment
is expected to hold major market share in the global attention deficit
hyperactivity disorder (ADHD) therapeutics market during the forecast period,
owing to increasing prevalence of attention deficit hyperactivity disorder
(ADHD) in adult population globally
Among distribution channel,
retail pharmacies segment is expected to hold major market share in the global
attention deficit hyperactivity disorder (ADHD) therapeutics market during the
forecast period, owing to increasing number of retail pharmacies & chain
stores, easy access of products, and strategic tie-ups between major companies
& retail pharmacies
Key players operating in the
global attention deficit hyperactivity disorder (ADHD) therapeutics market
include Amneal Pharmaceuticals, Inc., Eli Lilly And Company, Janssen
Pharmaceuticals, Inc., Noven Pharmaceuticals, Inc., RespireRx Pharmaceuticals
Inc., Otsuka Pharmaceutical Co., Ltd, Neos Therapeutics, Inc., American Brivision
(Holding) Corporation, Novartis International AG, Takeda Pharmaceutical Company
Limited, GlaxoSmithKline plc., and Purdue Pharma L.P.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/830
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment